PPARG is a key regulator of fetal lung maturation (Lee et al., 2020), lung immunity (Nobs & Kopf, 2018), fibrosis (Deng et al., 2012), vasculature (Hart, 2008), and metabolism (Kökény et al., 2021), etc. PPARG is a promising target in lung pathologies such as chronic airway inflammation (Belvisi et al., 2006), asthma and COPD (Al Sharif, 2021; Byelan et al., 2017; Rogliani et al., 2018; Tseng, 2022), pulmonary vascular disease (Afdal & AbdelMassih, 2018), pulmonary artery hypertension (Hansmann et al., 2020), fibrosis (Milam et al., 2008), and cancer (Li et al., 2006). Here, PPARG is linked to pulmonary arterial hypertension.